Syndax Pharmaceuticals (SNDX) Assets Average (2016 - 2026)

Syndax Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $501.2 million for Q1 2026.

• In Q1 2026, Assets Average fell 26.59% year-over-year to $501.2 million; the TTM figure through Mar 2026 stood at $501.2 million (down 26.59% YoY), while the FY2025 annual figure was $627.3 million, down 6.22% from the prior year.
• Assets Average for Q1 2026 stood at $501.2 million, down from $540.7 million in the prior quarter.
• The five-year high for Assets Average was $682.8 million in Q1 2025, with the low at $383.1 million in Q3 2022.
• The 5-year median for Assets Average is $501.2 million (2026), against an average of $502.3 million.
• The sharpest annual moves came in 2022 and 2026: Assets Average jumped 52.68% in 2022, then dropped 26.59% in 2026.
• Syndax Pharmaceuticals' Assets Average stood at $428.5 million in 2022, then advanced by 18.11% to $506.1 million in 2023, then increased by 13.69% to $575.3 million in 2024, then retreated by 6.01% to $540.7 million in 2025, then retreated by 7.32% to $501.2 million in 2026.
• Business Quant data shows SNDX's Assets Average at $501.2 million in Q1 2026, $540.7 million in Q4 2025, and $574.0 million in Q3 2025.